What we're reading, July 28, 2016: CMS released first hospital quality ratings; Anthem is prepared to fight the government over Cigna purchase; and regulations are falling behind stem cell clinics.
Of the 3617 hospitals rated in CMS’ first hospital quality rating, just 102 received the top rating of 5 stars. According to Kaiser Health News, many of the nation’s best-known hospitals received average or below-average scores as part of the controversial rating system. Hospitals argue the ratings do not do enough to factor in the health of the patients being treated, which makes the hospitals that treat tougher cases look bad.
Anthem is prepared to fight the US Department of Justice (DOJ)’s efforts to block its acquisition of Cigna. Expecting to lose money on plans sold under the Affordable Care Act, Anthem is arguing that a merger with Cigna would let it negotiate better prices and pass savings on to consumers, reported Reuters. Last week, the DOJ sued to block Anthem’s acquisition of Cigna and Aetna’s purchase of Humana.
Although stem cell therapies are mostly theory at this point, new stem cell clinics are spreading as regulations fall behind. The New York Times blog The Upshot took a look at the world of stem cell clinics and how they are operating by working around the current laws in place. FDA does allow clinics to inject patients with their own stem cells, as long as cells meet certain criteria, but some of the treatments being advertised seem to flout FDA regulations.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More